Anti-CD19 CAR T cells generated from CD4+ TN and TCM cells exhibited a higher expression of CD62L and had favorable effects on survival of tumor-bearing mice compared to treatment with CAR T cells generated from CD4+ TEM. This evidence concerns the gene CD19 and neoplasm.